Kailera Therapeutics (KLRA) Earnings Analysis
Kailera Therapeutics (KLRA) has no confirmed upcoming earnings date. Last quarter (2026-05-26) it missed with EPS -3,650 USD vs -0.775 USD est (-470867.7%). It has beaten estimates in 0/1 recent quarters (0%). Trailing P/E -14.12.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does KLRA next report earnings?
No confirmed upcoming earnings date is currently scheduled for KLRA. This page updates as the calendar is published.
KLRA earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-26 | -3,650 USD | -0.775 USD | -470867.7% | Miss |
Beat rate: 0/1 (0%) over reported quarters with consensus data.
KLRA valuation and analyst view
| Trailing P/E | -14.12 |
|---|---|
| Trailing EPS | -1.26288 USD |
| Price / book | -5.89 |
| Dividend yield | 0.00% |
| Market cap | 2.36B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Kailera Therapeutics (KLRA)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for KLRA. This page updates as the calendar is published.
Did KLRA beat earnings last quarter?
In its 2026-05-26 report, KLRA posted EPS of -3650 USD versus a -0.775 USD estimate — a miss of 470867.7%.
What is KLRA's earnings track record?
Over the last 1 reported quarters with consensus data, KLRA beat estimates 0 times (0%).
What is KLRA's current P/E ratio and EPS?
KLRA trades at a trailing P/E of -14.12 on trailing EPS of -1.2628787583911534 USD.
What do analysts rate KLRA?
KLRA has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.